Your shopping cart is currently empty

LY518674 (LY-674) decreases triglycerides and increases HDL-C and is used for the treatment of atherosclerosis. LY518674 is an effective and selective PPARα agonist (EC50: 42 nM for human PPARα).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $179 | In Stock | In Stock | |
| 5 mg | $378 | In Stock | In Stock | |
| 10 mg | $562 | In Stock | In Stock | |
| 25 mg | $892 | In Stock | In Stock | |
| 50 mg | $1,220 | In Stock | In Stock | |
| 100 mg | $1,650 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $418 | In Stock | In Stock |
| Description | LY518674 (LY-674) decreases triglycerides and increases HDL-C and is used for the treatment of atherosclerosis. LY518674 is an effective and selective PPARα agonist (EC50: 42 nM for human PPARα). |
| Targets&IC50 | PPARα:42 nM (EC50 human) |
| In vivo | LY518674 decreases triglycerides and increased HDL-C in vivo[2]. LY518674 significantly enhances apolipoprotein A-I (apoA-I) turnover without a major impact on steady-state levels of apoA-I or high-density lipoprotein-cholesterol (HDL-C) [3]. |
| Synonyms | LY-674 |
| Molecular Weight | 409.48 |
| Formula | C23H27N3O4 |
| Cas No. | 425671-29-0 |
| Smiles | Cc1ccc(Cn2[nH]c(CCCc3ccc(OC(C)(C)C(O)=O)cc3)nc2=O)cc1 |
| Relative Density. | 1.21g/cm3 |
| Storage | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 250 mg/mL (610.53 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (12.21 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.